Barclays’s PaxMedica, Inc. Common Stock PXMD Stock Holding History

Barclays’s Portfolio PXMD Stock Details PXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$204	–	5459
2022 Q4	$204	Buy	+6	New	+$214	﹤0.01%	5180

Other funds holding PXMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Barclays's PXMD Position: Q1 2023 in Review

Barclays sold out of PaxMedica, Inc. Common Stock (PXMD) in Q1 2023, closing a stake of 6 shares — an estimated $204 sold.

Barclays first reported a position in PXMD in Q4 2022 and held it in 1 quarter. The position peaked at $204 in Q4 2022. 10 funds tracked by Wall St. Rank hold PXMD as of Q1 2023.

Barclays reported no remaining PaxMedica, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Barclays sold 6 PaxMedica, Inc. Common Stock shares in Q1 2023, an estimated $204.
Barclays first reported a position in PaxMedica, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Barclays's PaxMedica, Inc. Common Stock position peaked at $204 in Q4 2022.
10 funds tracked by Wall St. Rank held PaxMedica, Inc. Common Stock as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.